halozyme therapeutics inc. - HALO
HALO
Close Chg Chg %
72.96 -1.14 -1.56%
Closed Market
71.82
-1.14 (1.56%)
Volume: 2.17M
Last Updated:
Jan 15, 2026, 4:00 PM EDT
Company Overview: halozyme therapeutics inc. - HALO
HALO Key Data
| Open $72.81 | Day Range 70.75 - 73.76 |
| 52 Week Range 47.50 - 79.50 | Market Cap $8.58B |
| Shares Outstanding 117.60M | Public Float 116.26M |
| Beta 0.94 | Rev. Per Employee N/A |
| P/E Ratio 15.06 | EPS $4.90 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.73M |
HALO Performance
| 1 Week | 0.68% | ||
| 1 Month | 8.33% | ||
| 3 Months | 8.85% | ||
| 1 Year | 33.14% | ||
| 5 Years | 53.83% |
HALO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About halozyme therapeutics inc. - HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
HALO At a Glance
Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego, California 92130
| Phone | 1-858-794-8889 | Revenue | 1.02B | |
| Industry | Biotechnology | Net Income | 444.09M | |
| Sector | Health Technology | 2024 Sales Growth | 22.438% | |
| Fiscal Year-end | 12 / 2025 | Employees | 350 | |
| View SEC Filings |
HALO Valuation
| P/E Current | 15.065 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.933 |
| Price to Sales Ratio | 6.094 |
| Price to Book Ratio | 16.182 |
| Price to Cash Flow Ratio | 12.92 |
| Enterprise Value to EBITDA | 11.265 |
| Enterprise Value to Sales | 7.021 |
| Total Debt to Enterprise Value | 0.216 |
HALO Efficiency
| Revenue/Employee | 2,900,925.714 |
| Income Per Employee | 1,268,831.429 |
| Receivables Turnover | 3.292 |
| Total Asset Turnover | 0.521 |
HALO Liquidity
| Current Ratio | 7.803 |
| Quick Ratio | 6.783 |
| Cash Ratio | 4.285 |
HALO Profitability
| Gross Margin | 77.301 |
| Operating Margin | 54.315 |
| Pretax Margin | 54.872 |
| Net Margin | 43.739 |
| Return on Assets | 22.791 |
| Return on Equity | 198.419 |
| Return on Total Capital | 23.369 |
| Return on Invested Capital | 25.315 |
HALO Capital Structure
| Total Debt to Total Equity | 422.324 |
| Total Debt to Total Capital | 80.855 |
| Total Debt to Total Assets | 71.007 |
| Long-Term Debt to Equity | 420.386 |
| Long-Term Debt to Total Capital | 80.484 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Halozyme Therapeutics Inc. - HALO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 443.31M | 660.12M | 829.25M | 1.02B | |
Sales Growth
| +65.67% | +48.91% | +25.62% | +22.44% | |
Cost of Goods Sold (COGS) incl D&A
| 81.41M | 182.45M | 266.13M | 230.47M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.00M | 49.64M | 84.86M | 81.31M | |
Depreciation
| 3.00M | 6.49M | 11.08M | 10.26M | |
Amortization of Intangibles
| - | 43.15M | 73.77M | 71.05M | |
COGS Growth
| +87.73% | +124.11% | +45.87% | -13.40% | |
Gross Income
| 361.90M | 477.66M | 563.12M | 784.86M | |
Gross Income Growth
| +61.40% | +31.99% | +17.89% | +39.38% | |
Gross Profit Margin
| +81.64% | +72.36% | +67.91% | +77.30% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 86.00M | 188.23M | 225.54M | 233.38M | |
Research & Development
| 35.67M | 66.61M | 76.36M | 79.05M | |
Other SG&A
| 50.32M | 121.63M | 149.18M | 154.34M | |
SGA Growth
| +7.53% | +118.89% | +19.82% | +3.48% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 20.96M | 24.61M | (13.20M) | |
EBIT after Unusual Expense
| 254.94M | 264.82M | 350.77M | 551.48M | |
Non Operating Income/Expense
| 1.10M | 1.05M | 16.32M | 23.75M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 7.53M | 16.95M | 18.76M | 18.09M | |
Interest Expense Growth
| -63.07% | +125.18% | +10.71% | -3.56% | |
Gross Interest Expense
| 7.53M | 16.95M | 18.76M | 18.09M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 248.52M | 248.92M | 348.33M | 557.13M | |
Pretax Income Growth
| +92.20% | +0.16% | +39.94% | +59.94% | |
Pretax Margin
| +56.06% | +37.71% | +42.01% | +54.87% | |
Income Tax
| (154.19M) | 46.79M | 66.73M | 113.04M | |
Income Tax - Current - Domestic
| 1.24M | 8.68M | 30.68M | 111.90M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (155.43M) | 38.11M | 36.05M | 1.14M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 402.71M | 202.13M | 281.59M | 444.09M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 402.71M | 202.13M | 281.59M | 444.09M | |
Net Income Growth
| +211.97% | -49.81% | +39.31% | +57.71% | |
Net Margin Growth
| +90.84% | +30.62% | +33.96% | +43.74% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 402.71M | 202.13M | 281.59M | 444.09M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 402.71M | 202.13M | 281.59M | 444.09M | |
EPS (Basic)
| 2.8633 | 1.4771 | 2.1345 | 3.5016 | |
EPS (Basic) Growth
| +202.13% | -48.41% | +44.51% | +64.05% | |
Basic Shares Outstanding
| 140.65M | 136.84M | 131.93M | 126.83M | |
EPS (Diluted)
| 2.7433 | 1.4375 | 2.0984 | 3.4313 | |
EPS (Diluted) Growth
| +200.64% | -47.60% | +45.98% | +63.52% | |
Diluted Shares Outstanding
| 146.80M | 140.61M | 134.20M | 129.42M | |
EBITDA
| 278.90M | 339.07M | 422.43M | 632.79M | |
EBITDA Growth
| +89.03% | +21.58% | +24.58% | +49.80% | |
EBITDA Margin
| +62.91% | +51.37% | +50.94% | +62.32% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 77.625 | |
| Number of Ratings | 10 | Current Quarters Estimate | 1.733 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 8.223 | |
| Last Quarter’s Earnings | 1.895 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 6.13 | Next Fiscal Year Estimate | 9.774 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 6 | 5 |
| Mean Estimate | 1.73 | 1.93 | 8.22 | 9.77 |
| High Estimates | 1.97 | 2.16 | 8.93 | 10.37 |
| Low Estimate | 1.63 | 1.75 | 7.51 | 9.05 |
| Coefficient of Variance | 9.22 | 8.88 | 5.88 | 5.55 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Halozyme Therapeutics Inc. - HALO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Halozyme Therapeutics Inc. - HALO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 2, 2025 | Jeffrey William Henderson Director | 33,108 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.05 per share | 2,120,567.40 |
| Feb 28, 2025 | Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER | 186,153 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.01 per share | 10,798,735.53 |
| Feb 28, 2025 | Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER | 185,453 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.67 per share | 10,880,527.51 |
| Feb 28, 2025 | Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER | 176,053 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.09 per share | 10,226,918.77 |
| Feb 28, 2025 | Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER | 175,453 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.65 per share | 10,290,318.45 |
| Feb 28, 2025 | Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER | 173,856 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.25 per share | 10,127,112.00 |
| Feb 28, 2025 | Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER | 173,756 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.74 per share | 10,206,427.44 |
| Feb 24, 2025 | Helen I. Torley PRESIDENT AND CEO; Director | 71,038 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | 21,327 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | 22,603 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Mark Snyder SVP, CHIEF LEGAL OFFICER | 21,327 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Mark Snyder SVP, CHIEF LEGAL OFFICER | 22,603 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Helen I. Torley PRESIDENT AND CEO; Director | 67,027 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Helen I. Torley PRESIDENT AND CEO; Director | 96,155 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Mark Snyder SVP, CHIEF LEGAL OFFICER | 7,269 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Mark Snyder SVP, CHIEF LEGAL OFFICER | 30,050 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Helen I. Torley PRESIDENT AND CEO; Director | 23,260 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | 6,935 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | 28,662 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |